Kalaris Therapeutics Inc
NASDAQ:KLRSBiotechnology
+$0.16 today
- Market cap
- $54.75M
- Beta
- 0.14
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$1.86
Volume 0.07M
Average 0.08M
KLRS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Kalaris Therapeutics IncNASDAQ: KLRS
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $4.25M fell 1.7% year over year, ahead of the -41.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 17.0% from the prior quarter. Over 3 fiscal years it compounded at +90.0% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -64.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.25M+17.0% QoQ
- Last fiscal yearDec 2025
- $15.39M-64.1% YoY
- LTMMar 2026
- $15.32M-41.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1.7% | -100.0% | -98.3 pp |
| 1 year | -64.1% | -100.0% | -35.9 pp |
| 3-year CAGR | +90.0% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 15.39M USD
- Year-over-year change
- -64.1%
- 4-year CAGR
- -25.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.39M | -64.1% |
| FY2024 | 2024-12-31 | 42.92M | +2342.6% |
| FY2023 | 2023-12-31 | 1.76M | -21.7% |
| FY2022 | 2022-12-31 | 2.24M | -95.4% |
| FY2021 | 2021-12-31 | 49.08M | — |
Selling, General & Admin vs competitors
How KLRS compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -41.8% is the lowest of 9, against a peer median of -6.6%.
- Over three fiscal years its annual growth of +90.0% compares with a peer median of -1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.33M USD | -27.9% | -11.7% | 35.5% | |
| LTM Mar 2026 | $24.75M USD | -6.4% | -9.4% | 347.5% | |
IMAImageneBio Inc | LTM Mar 2026 | $21.2M USD | -9.1% | -2.3% | — |
| FY2025 | $20.34M USD | +5.8% | -0.8% | 31781.3% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $20.27M USD | +8.2% | -0.8% | — |
| LTM Mar 2026 | $17.37M USD | -6.9% | -4.3% | 1736.5% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $15.32M USD | -41.8% | +90.0% | — |
| LTM Mar 2026 | €14.24M EUR | -27.6% | +7.0% | 48538.7% | |
| LTM Mar 2026 | $8.11M USD | +9.0% | +0.2% | — | |
| Peer median (excluding KLRS) | — | -6.6% | -1.5% | 1736.5% | |
Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.12M | 0 | 0 | 0 | 13K |
| Gross Profit | (1.12M) | 0 | 0 | 0 | (13K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 119.62M | 11.76M | 11.71M | 12.34M | 30.75M |
| Selling, General & Admin | 49.08M | 2.24M | 1.76M | 42.92M | 15.39M |
| Operating Expenses | 168.7M | 14.01M | 13.46M | 55.26M | 46.14M |
| Depreciation & Amortization | 1.12M | 0 | 0 | 0 | 13K |
| EBITDA | (169.84M) | (15.25M) | (14.01M) | (58.77M) | (41.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (169.82M) | (14.01M) | (13.46M) | (55.26M) | (46.15M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 1.32M | 0 | 0 | 5.49M | 0 |
| Interest Expense | 0 | 235K | 687K | 0 | 1.44M |
| Other Income / Expenses | (1.14M) | (1.48M) | (1.24M) | (3.51M) | 2.71M |
| Income Before Tax | (170.96M) | (15.49M) | (14.7M) | (58.77M) | (43.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1.01M | 0 | 0 | 0 | 0 |
| Net Income | (171.96M) | (15.49M) | (14.7M) | (58.77M) | (43.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (63.00) | (50.62) | (42.09) | (11.73) | (2.85) |
| EPS (Diluted) | (63.00) | (50.62) | (42.09) | (11.73) | (2.85) |
| Weighted Avg Shares | 2.73M | 3.33M | 4.52M | 5.01M | 15.27M |
| Weighted Avg Shares (Diluted) | 2.73M | 3.33M | 4.52M | 5.01M | 15.27M |
Kalaris Therapeutics Inc
NASDAQ:KLRS
Intrinsic Alpha fair value
Locked
Current Price
$2.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.